Journals / Klinik Psikofarmakoloji Bülteni / 2009 / Cilt: 19 - Sayı: 2

Major depresif bozukluğu olan hastalarda essitaloprama folik asit ekleme tedavisi ve homosistein, folik asit, B-12 vitamini düzeyleri

Adjuvant folate with escitalopram treatment and homocystein, folate, vitamin B-12 levels in patients with major depressive disorder

Pages
135–142
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, patients had higher mean plasma tHcy (z= -2.72, p= 0.006) and lower urine tHcy levels (z= -6.48, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Folate supplementation in Major Depressive Disorder (MDD) has been investigated in clinical studies with promising results.
📊
Key Findings & Data:Secondary objectives were to evaluate the relationships between the levels of three metabolites [Folic acid; total homocysteine (tHcy); vitamin B12] and psychometric measurements in patients with MDD.Methods: Thirty five patients with major depression were randomly divided into two groups; receiving either 2.5 mg folic acid in addition to 10 mg escitalopram (n=20) and receiving only 10 mg escitalopram (n=15) daily.
💡
Conclusion & Impact:In addition, patients had higher mean plasma tHcy (z= -2.72, p= 0.006) and lower urine tHcy levels (z= -6.48, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Folate supplementation in Major Depressive Disorder (MDD) has been investigated in clinical studies with promising results. The primary objective of this trial was to study the effect of adjuvant folate treatment with escitalopram in MDD patients. Secondary objectives were to evaluate the relationships between the levels of three metabolites [Folic acid; total homocysteine (tHcy); vitamin B12] and psychometric measurements in patients with MDD.Methods: Thirty five patients with major depression were randomly divided into two groups; receiving either 2.5 mg folic acid in addition to 10 mg escitalopram (n=20) and receiving only 10 mg escitalopram (n=15) daily. The comparison group consisted of 32 healthy volunteers. All the patients were evaluated by using the Montgomery- Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression (CGI) scale. Clinical response was defined by at least a 50 % reduction in baseline MADRS total scores. The depressive symptoms of patients, samples of folate, vit-B12 and tHcy levels were measured at baseline and after 6 weeks of treatment.Results: The clinical response to treatment was 53.4% (n=35) in all patients. A percentage of 80% of patients, who received only escitalopram, showed a good response (50% reduction in score) as compared to 35% of patients who received adjuvant folic acid supplementation beside escitalopram (P =0.016). There was a negative correlation between serum folate and plasma tHcy levels of patients at baseline (Spearman r=-0.426 and p=0.011). In addition, patients had higher mean plasma tHcy (z= -2.72, p= 0.006) and lower urine tHcy levels (z= -6.48, p

Özet

Amaç: Tıbbi yazında Major Depresif Bozukluğu (MDB) olan ve antidepresan ilaç verilen hastalarda folik asit ekleme tedavisinin klinik iyileşmeye katkısı olduğunu ortaya koyan çalışmalar vardır. Bu çalışmanın öncelikli amacı; ilk kez psikotrop tedavi alacak olan MDB tanısı konan hastalara essitalopram tedavisine folik asit eklemenin tedaviye olan katkısını değerlendirmektir. İkincil amaç ise, MDB hastalarında psikometrik ölçümler, folik asit, total homosistein (tHst), B- 12 vitamini seviyeleri arasındaki ilişkiyi araştırmaktır.Yöntem: Çalışma örneklemini oluşturan toplam 35 MDB hastası iki gruba ayrıldı: Ardışık olarak bir gruba; günlük 10 mg essitaloprama ek olarak 2,5 mg folik asit verilirken (n=20), diğer gruba sadece günde 10 mg essitalopram verildi (n=15). Tüm hastalar DSM-IV’e göre major depresyon tanı kriterlerini karşılamakta olup, kontrol grubu 32 sağlıklı gönüllüden oluşmaktaydı. Depresyon semptomlarının şiddeti, Montgomery-Asberg Depresyon Değerlendirme Ölçeği (MADDÖ) ile değerlendirilirken, hastalığın şiddeti Klinik Global Değerlendirme ölçeğinin (KGD) uygun modülü kullanılarak ölçüldü. MADDÖ de başlangıç skoruna göre %50 azalma sağlanması tedaviye yanıt olarak kabul edildi. Gruplarda depresif semptom şiddeti, Folik asit, B-12 vitamini ve tHst seviyeleri tedavi öncesi ve tedavi sonrası (altıncı hafta) ölçülerek karşılaştırılmıştır.Bulgular: Tüm MDB hastalarının essitalopram tedavisine klinik yanıtı %53,4 olarak saptanırken (n=35), başlangıçtaki ölçümlerde tüm hastaların serum folik asit ve plazma tHst seviyeleri arasında belirgin negatif korelasyon vardı (Spearmanr=-0.426 ve p=0.011). Yalnız essitalopram alan hastaları n %80’i tedaviye olumlu yanıt verirken, folik asit ekleme tedavisi alan hastaların cevap oranı %35 olarak tespit edildi (P =0.016). Ayrıca hastaların plazma tHst düzeyleri sağlıklı kontrollere göre daha yüksekken (z= -2.72, p= 0.006) idrar tHst düzeyleri daha düşük saptanmıştır(z= -6.48, p

🔖

Cite This Article

SEMİZ, Ü. B., YILMAZ, O., İPÇİOĞLU, O. M., GÜLSÜN, M., ÖZCAN, Ö., ATEŞ, M. A., GEÇİCİ, Ö., EBRİNÇ, S., ÇETİN, M., BAŞOĞLU, C., KILIÇ, S., ALGÜL, A. (2022). Major depresif bozukluğu olan hastalarda essitaloprama folik asit ekleme tedavisi ve homosistein, folik asit, B-12 vitamini düzeyleri. Klinik Psikofarmakoloji Bülteni, Cilt: 19 - Sayı: 2, 135–142. https://ajindex.com/articles/574274

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Murray CJL, Lopez AD. Global mortality, disability and the contribution of risk factors. Global Burden of Disease Study. Lancet. 1997;349:1436-1442
  2. Parker G, Mitchell P, Wilhelm K, Menkes DB, Snowdon J, Schweitzer I, Grounds D, Skerrit P, Roy K, Hadzi-Pavlovic D. Are the newer antidepressant drugs as effective as established physical treatments? Results from an Australasian clinical panel review. Australian and New Zealand Journal of Psychiatry 1999; 33: 874-881 3. Botez MI, Young SN, Bachevalier J, Gauthier S. Folate deficiency and decreased brain 5-hydroxytryptamine synthesis in man and rat. Nature. 1979; 278: 182-183
  3. Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry 2002;14:33-38
  4. Carney MWP. Serum folate values in 423 psychiatric patients. British Medical Journal. 1967; 4: 512-516
  5. Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T. Folate, vitamin B12, and homocysteine in major depressive disorder. American Journal of Psychiatry 1997; 154: 426-428 7. Harden CL, Goldstein MA. Mood disorders in patients with epilepsy: epidemiology and management. CNS Drugs 2002;16: 291-302
  6. Reynolds EH, Preece M, Bailey J, Coppen A. Folate deficiency in depressive illness. Br. J. Psychiatry 1970; 117: 287-292
  7. Abou-Saleh MT, Coppen A. Subjective side-effects of amitriptyline and lithium in affective disorders. Br. J. Psychiatry 1983; 142: 391-397
  8. Abou-Saleh MT, Coppen A. Serum and red blood cell folate in depression. Acta Psychiatr Scand 1989; 80: 78-82
  9. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH: Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000; 69:228-232
  10. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MM. Vitamin B12, Folate, and Homocysteine in Depression: The Rotterdam Study. Am J Psychiatry 2002; 159: 2099-2101
  11. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000; 15: 6920-6926
  12. Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 2002; 70: 694-702
  13. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plas